Cover Image

Comparative analysis of adverse event risks in breast cancer patients receiving pembrolizumab combined with paclitaxel versus paclitaxel monotherapy: insights from the FAERS database

ObjectiveThis study aimed to evaluate the risk of adverse events (AEs) in breast cancer patients treated with pembrolizumab combined with paclitaxel versus those receiving pembrolizumab or paclitaxel monotherapy, using the FDA Adverse Event Reporting System (FAERS) database.MethodsData were extracte...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yilun Li (Author), Xiaolu Yang (Author), Li Ma (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Signal detection and analysis of adverse events associated with Genvoya® based the FAERS database
by: Chengliang Wang, et al.
Published: (2024)

The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database
by: Huaju Yang, et al.
Published: (2023)

The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database
by: Xiaogan Wang, et al.
Published: (2024)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023)

Analysis of eplerenone in the FDA adverse event reporting system (FAERS) database: a focus on overall patient population and gender-specific subgroups
by: Xin Guan, et al.
Published: (2024)

Neratinib safety evaluation: real-world adverse event analysis from the FAERS database
by: Yunhe Fan, et al.
Published: (2024)

Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database
by: Chuanli Yang, et al.
Published: (2024)

Safety assessment of tranexamic acid: real-world adverse event analysis from the FAERS database
by: Ningsheng Tian, et al.
Published: (2024)

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
by: Ming-Tao Wen, et al.
Published: (2024)

Mining and evaluation of adverse event signals for capmatinib based on the FAERS database
by: Xinnan Chen, et al.
Published: (2024)

Analysis of Opioid-Related Adverse Events in Japan Using FAERS Database
by: Risako Hirai, et al.
Published: (2023)

Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
by: Shangze Li, et al.
Published: (2024)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
by: Fan Zou, et al.
Published: (2023)

Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database
by: Yanjing Zhang, et al.
Published: (2024)

Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database
by: PingPing Long, et al.
Published: (2024)

CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017-2023)
by: Jing Shi, et al.
Published: (2024)

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases
by: Qian Liu, et al.
Published: (2024)

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
by: Lazzaro C, et al.
Published: (2013)

Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database
by: Shihao Chen, et al.
Published: (2024)

Adverse event profile of albumin-bound paclitaxel: a real-world pharmacovigilance analysis
by: Yuanqiong Duan, et al.
Published: (2024)

Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database
by: Shi-Nan Wu, et al.
Published: (2024)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
by: Jianxing Zhou, et al.
Published: (2022)

A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases
by: Shupeng Zou, et al.
Published: (2024)

The mechanism of paclitaxel induced damage on placental trophoblast cells
by: Yang Yu, et al.
Published: (2024)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
by: Yunyan Pan, et al.
Published: (2024)

Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database
by: Zhiwen Fu, et al.
Published: (2024)

Antihypertensive drug-associated adverse events in osteoarthritis: a study of a large real-world sample based on the FAERS database
by: Zijian Guo, et al.
Published: (2024)

A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
by: Liyuan Liu
Published: (2024)

Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database
by: Feng Liu, et al.
Published: (2024)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022)

Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database
by: Xiping Yang, et al.
Published: (2024)

Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
by: Clarissa Lam, et al.
Published: (2022)

Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS)
by: KaiLi Mao, et al.
Published: (2024)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Zhuo Ma, et al.
Published: (2021)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
by: Si Su, et al.
Published: (2023)

Unleashing the link between the relaxation of the COVID-19 control policy and residents' mental health in China: the mediating role of family tourism consumption
by: Yilun He, et al.
Published: (2023)

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
by: Fan Zou, et al.
Published: (2024)

Pharmacokinetic evaluation of paclitaxel, albumin-binding paclitaxel, and liposomal-encapsulated albumin-binding paclitaxel upon gastric subserosal administration
by: Yoontaek Lee, et al.
Published: (2024)

Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)
by: Ruibo Li, et al.
Published: (2024)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023)